VRTX · NASDAQ · STOCK
Vertex Pharmaceuticals (VRTX) Stock Analysis
$548.03
52W $374.17 – $555.32
62/100
$139.10B
31.6
0.30
Is VRTX Bullish or Bearish?
Bullish.
Innellis AI committee rates Vertex Pharmaceuticals (VRTX) Buy with a composite score of 62/100
, based on 6 analysts with 50% agreement.
Last updated August 23, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +12.67 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -7.33 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock — Risk
Bear Case
- P/E of 30.7 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 20.7% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 23, 2026
Overall Committee Score
62/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 23%
of 192 Healthcare peers
Value Analyst
neutral
54
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 23.3% shows genuine earnings power backing the valuation
− P/E of 30.7 is moderate-to-rich
Growth Analyst
bullish
75
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst
neutral
59
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock
− Bollinger bandwidth of 20.7% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 30 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3069.37)
Investment Thesis Evolution
Committee score moved marginally from 62.3 to 62.3.
Comparing 2026-08-22 to 2026-08-23 (1 day apart).
Technical Analysis
RSI (14)
69.6
Neutral
MACD Histogram
4.455
Bullish Momentum
Trend Direction
Uptrend
Weekly: Downtrend
Market Structure
Hh Hl
Bollinger %B
0.91
Inside Bands
Price vs Moving Averages
EMA 9
$529.08
Above
EMA 21
$512.22
Above
EMA 50
$492.62
Above
EMA 200
$464.07
Above
Fundamental Analysis
Valuation
43
Growth
55
Profitability
100
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
31.6×
P/B Ratio
6.87×
PEG Ratio
1.41
Dividend Yield
0.00%
52W High
$555.32
52W Low
$374.17
Quality & Growth
ROE
2117.9%
ROA
1512.2%
Gross Margin
8603.6%
Operating Margin
3859.2%
Revenue Growth YoY
—
Debt / Equity
0.10
AI Fundamental Assessment
P/E ratio of 31.6 (rich relative to a 15-40x range); Price-to-book of 6.9x; PEG ratio of 1.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 21.2%; Return on assets of 15.1%; Net margin of 34.9%; Gross margin of 86.0%; Current ratio of 3.19 (healthy short-term liquidity); Debt-to-equity of 0.10; Free cash flow per share is positive (14.95); Most recent quarter missed estimates by 2.0%; EPS growth accelerating (-11.1% -> +5.8% QoQ); Average YoY EPS growth of 4.7%; Analyst estimates falling over recent quarters
Get the Full VRTX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →